首页 > 市场调查报告书 > 製药

骨疾病

市场调查报告书

商品编码

1622333

骨关节炎治疗市场规模、份额、成长分析、按解剖学、按药物类型、按治疗类型、按分销管道、按地区 - 行业预测，2025-2032 年

Osteoarthritis Treatment Market Size, Share, Growth Analysis, By Anatomy, By Drug Type (Analgesics, Nonsteroidal Anti-Inflammatory Drugs ), By Treatment Type, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: 2024年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2023年骨关节炎治疗市场规模为87.1亿美元，从2024年的94.5亿美元成长到2032年的181.5亿美元，预测期（2025-2032）预计复合年增长率为8.50%。

全球骨关节炎治疗市场正在强劲成长，这主要是由于骨关节炎盛行率上升和人口老化。随着预期寿命的延长，越来越多的老年人受到骨关节炎的影响，这增加了对有效管理策略的需求。医疗保健的进步刺激了对旨在减轻症状和改善患者生活品质的创新治疗解决方案的需求。此外，人们对治疗方案和早期疗育重要性的认识不断提高也有助于市场扩张。医疗保健提供者正在积极对患者进行有关骨关节炎及其危险因素的教育，以实现早期诊断和及时治疗。这种日益增长的意识正在推动对骨关节炎治疗产品的需求，并进一步推动市场趋势。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东/非洲
- 海湾合作委员会国家
- 南非
- 其他中东/非洲

竞争资讯

前5名企业对比
主要企业市场定位（2024年）
主要市场参与者所采取的策略
近期市场趋势
公司市场占有率分析（2024年）
主要企业简介
- 公司简介
- 产品系列分析
- 按细分市场分類的份额分析
- 收益与前一年同期比较（2022-2024）

主要企业简介

Sanofi（France）
Pfizer Inc.（USA）
Novartis AG（Switzerland）
Johnson & Johnson（USA）
GlaxoSmithKline plc（UK）
AbbVie Inc.（USA）
Eli Lilly and Company（USA）
Bayer AG（Germany）
Merck & Co., Inc.（USA）
Bristol Myers Squibb（USA）
AstraZeneca plc（UK）
Amgen Inc.（USA）
Haleon plc（UK）
Seikagaku Corporation（Japan）
Ono Pharmaceutical Co., Ltd.（Japan）
Assertio Holdings, Inc.（USA）
Zimmer Biomet Holdings, Inc.（USA）
Ferring Pharmaceuticals（Switzerland）
Genascence Corporation（USA）

结论和建议

简介目录

Product Code: SQMIG35A2305

Osteoarthritis Treatment Market size was valued at USD 8.71 Billion in 2023 and is poised to grow from USD 9.45 Billion in 2024 to USD 18.15 Billion by 2032, growing at a CAGR of 8.50% during the forecast period (2025-2032).

The global osteoarthritis treatment market is experiencing robust growth, primarily fueled by the rising incidence of osteoarthritis and an aging demographic. As life expectancy improves, more elderly individuals are becoming susceptible to this condition, thereby escalating the demand for effective management strategies. Advancements in healthcare have catalyzed the need for innovative treatment solutions aimed at alleviating symptoms and enhancing patient quality of life. Additionally, heightened awareness surrounding treatment options and the significance of early intervention are contributing to this market expansion. Healthcare providers are proactively educating patients about osteoarthritis and its risk factors, leading to earlier diagnosis and prompt treatment. This increasing awareness is driving the demand for osteoarthritis treatment products, further propelling market dynamics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Osteoarthritis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Osteoarthritis Treatment Market Segmental Analysis

Global Osteoarthritis Treatment Market is segmented by anatomy, drug type, treatment type, distribution channel and region. Based on anatomy, the market is segmented into knee osteoarthritis, hip osteoarthritis, hand osteoarthritis and small joint osteoarthritis. Based on drug type, the market is segmented into analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, visco supplementation agents and others. Based on treatment type, the market is segmented into medication, surgery and therapy. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Osteoarthritis Treatment Market

The escalating prevalence of obesity worldwide plays a crucial role in the rising rates of osteoarthritis, thereby significantly influencing the osteoarthritis treatment market. As more individuals grapple with obesity, the incidence of osteoarthritis also climbs, prompting a heightened demand for effective treatment solutions. This trend is particularly evident as obese patients typically necessitate multifaceted strategies to manage their osteoarthritis symptoms. Consequently, the link between increasing obesity rates and the growing need for osteoarthritis treatments creates a compelling driver for market expansion, highlighting the urgent need for healthcare providers to offer targeted therapies and interventions to this affected population.

Restraints in the Osteoarthritis Treatment Market

One of the primary obstacles facing the osteoarthritis treatment market is the scarcity of disease-modifying therapies. Despite progress in research and treatment options, there is still an evident shortfall in effective therapies that can halt or alter the progression of osteoarthritis. This deficiency not only complicates the comprehensive management of the disease but also adversely affects the overall treatment success and quality of life for patients. Consequently, the lack of such innovative therapeutic approaches serves as a significant constraint, limiting potential advancements in the care and rehabilitation of individuals suffering from this debilitating condition.

Market Trends of the Osteoarthritis Treatment Market

The global Osteoarthritis Treatment market is witnessing a significant trend towards personalized and multimodal treatment strategies, reflecting a deeper understanding of the disease's complexity and varied patient responses. As the elderly population continues to grow, healthcare providers are moving away from traditional methods focused solely on pain management with NSAIDs and analgesics. Instead, they are increasingly incorporating physical therapy, lifestyle modifications, and innovative therapies such as biologics and regenerative medicine to create tailored treatment plans. This shift not only aims to alleviate symptoms but also to improve overall joint function and quality of life, positioning these personalized approaches at the forefront of osteoarthritis care.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Patent Analysis

Global Osteoarthritis Treatment Market Size by Anatomy & CAGR (2025-2032)

Market Overview
Knee Osteoarthritis
Hip Osteoarthritis
Hand Osteoarthritis
Small Joint Osteoarthritis

Global Osteoarthritis Treatment Market Size by Drug Type & CAGR (2025-2032)

Market Overview
Analgesics
- Acetaminophen
- Opioids
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Ibuprofen
- Naproxen
Corticosteroids
- Oral Corticosteroids
- Injectable Corticosteroids
Visco Supplementation Agents
- Hyaluronic Acid
Others
- Disease-Modifying Osteoarthritis Drugs (DMOADs)

Global Osteoarthritis Treatment Market Size by Treatment Type & CAGR (2025-2032)

Market Overview
Medication
Surgery
- Joint Replacement
- Arthroscopy
- Osteotomy
Therapy
- Physical Therapy
- Occupational Therapy

Global Osteoarthritis Treatment Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Osteoarthritis Treatment Market Size & CAGR (2025-2032)

North America (Anatomy, Drug Type, Treatment Type, Distribution Channel)
- US
- Canada
Europe (Anatomy, Drug Type, Treatment Type, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Anatomy, Drug Type, Treatment Type, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Anatomy, Drug Type, Treatment Type, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Anatomy, Drug Type, Treatment Type, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Haleon plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seikagaku Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ono Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Assertio Holdings, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zimmer Biomet Holdings, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genascence Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments